LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
- Sponsor:
- SWOG
- Sponsor Study ID:
- LUNGMAP
- CTO #:
- 103247
- NCT Number:
- NCT03851445
- Phase:
- II/III
- Protocol Type:
- Screening
- Age Group:
- Adults
- Disease Sites:
- Lung
- Study Objectives:
- This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Affiliate Principal Investigator, Lupak, Oleksandra, at oll203@musc.edu .
- Principal Investigator, Wrangle, John, at wrangle@musc.edu .
- Study Coordinator, Shealor, Jessica, at shealorj@musc.edu .
-
Ralph H. Johnson VAMC
- Study Coordinator, Jeter, Kathy, at katherine.jeter2@va.gov .
Trial opened at the following institutions:
Medical University of South Carolina, Ralph H. Johnson VAMC